FIGURE

Figure 8

ID

ZDB-FIG-221226-287

Publication

Ruzic et al., 2022 - Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation

Other Figures

All Figure Page

Back to All Figure Page

Figure 8

In vivo toxicity assessment of 1-benzhydryl-piperazine-based HDAC inhibitors 8b and 9b in the zebrafish (Danio rerio) model. (A) Acute toxicity was assessed using wild type (AB) embryos exposed to different doses of tested molecules, and expressed as the LC₅₀ and EC₅₀ doses. Embryos were treated at 6 h post fertilization (hpf), and evaluated for survival, teratogenicity, cardiotoxicity, and hepatotoxicity at 120 hpf (n = 60 per a dose). (B) Embryos exposed to 50 µM of 8b were normally developed embryos, without signs of cardiotoxicity, hepatotoxicity, and teratogenicity. On the other hand, treatment with 9b in some embryos provoked pericardial edema (arrow), weakly resorbed yolk (asterisk), malformed head (bracket) and jaw (arrowhead), no inflated swim bladder (dashed arrow), and decreased and dark liver (outlined). No adverse effect on the liver was detected at 50 µM of 8b, while reduced liver size and darkening (necrosis) occurred in embryos exposed to 50 µM of 9b.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Pharmaceutics